Results showing the effectiveness of the vaccine in dogs were recently published in the journal Vaccine
The company today reported positive results of the clinical trial of its drug for the treatment of necrotizing soft tissue infections.
When Ovadia Lev, Professor of Environmental Chemistry and Health at The Hebrew University of Jerusalem, and his research team developed a new coating technology a few years ago, they thought it was an interesting outcome of their research in hydrogen peroxide solutions. However, they weren't sure what to do with it until they met a team of researchers looking for a simple way to synthesize new lithium-ion battery anode materials, such as graphene-tin oxide composites.
Tiltan Pharma is one of the portfolio companies of Integra Holdings, a biopharmaceutical holding company founded by Yissum, the technology transfer company of the Hebrew University of Jerusalem.
The blind have long used other senses -- including touch -- to compensate for their visual impairment. But a new study finds that when images are conveyed as sound, even the congenitally blind can distinguish among objects and their brains respond as if they are seeing.
Integra Holdings closes U.S. $ 7.0 million private financing
One of six promising orphan Drugs currently under development in Israel, AB103 was granted Fast Track and Orphan Drug designations by the FDA.
Drug developer Atox Bio announced today that the US Food and Drug Administration (FDA) has granted fast track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).
Hebrew U. medical researchers find a tiny peptide encoded by the HIV virus could hold the key to making cancer therapies more successful.
Novel biocontrol agent is environmentally-friendly, non-toxic and effective for a large variety of plants
The novel method uses a peptide derived from HIV to increase the sensitivity of cancer cells to radiotherapy and chemotherapy
When Scientific American recently wrote about the progress in artificial intelligence, it profiled two IBM supercomputers: Deep Blue, which defeated the world champion Gary Kasparov in chess, and the Jeopardy-winning Watson. The other company it profiled is the little-known Mobileye, an Israeli firm whose strength lies in EyeQ, a chip with a dimension of only one square centimeter.
Montreal venture capitalist Matthew Price-Gallagher is bullish on Israel. The successful high-tech entrepreneur has been to the country about 20 times in the last two years, attracted to its refreshing “can-do” approach to business – and science.
Price-Gallagher, president and CEO of Water Cluster Scientific Inc., is collaborating with the Hebrew University of Jerusalem and its affiliated technology transfer company, Yissum, on research and development.
Five researchers at the Hebrew University's Faculty of Agriculture reach commercial success through Yissum, the university's technology transfer company.
The Hebrew University of Jerusalem (HUJ) recently unveiled "Innovators Way," a permanent photo exhibition showcasing 27 university researchers whose genius is behind commercial products that have revolutionized the fields of health, safety, environment, agriculture, computer science and nutrition.
Innovators Way celebrates the researchers whose creative concepts reached an advanced enough stage to allow Yissum Research Development, the university’s technology transfer company, to patent, commercialize and market their inventions to Israeli and international companies.
Experimental work by a Hebrew University researcher involving stimulation of a cannabinoid receptor in the immune system has been shown to hold promise for the treatment of many neurological, inflammatory and other illnesses.
The agreement on behalf of the institute was made through Yissum, the technology transfer company of the Hebrew University. The program is designed to fund promising research that can lead to creating improved new health-care products, with the goal of having teams apply for follow-on funding through Drexel’s Coulter Translational Research Partnership program endowment or from other sources of translational research funding.
Yissum Technology Transfer Company of the Hebrew University of Jerusalem president and CEO Yaacov Michlin added that this activity creates high-quality jobs. He estimated that each $1 million in exports creates 15 jobs.
Five young researchers from the Hebrew University of Jerusalem will receive Kaye Innovation Awards on Wednesday for their research into type 1 diabetes, anti-inflammatory drugs, increasing wheat yields, activation of cannabinoid receptors in the immune system and treatment to halt over-immune responses.